Published in Clin Pharmacol Ther on July 01, 2007
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother (2009) 3.62
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol (2013) 2.08
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol (2013) 1.83
The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol (2010) 1.71
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol (2009) 1.67
Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti -tuberculosis therapy. In Silico Pharmacol (2014) 1.41
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol (2009) 1.22
Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn (2009) 1.16
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J Pharmacokinet Pharmacodyn (2009) 1.16
Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol (2009) 1.15
Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother (2012) 1.13
Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther (2014) 1.03
Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs (2011) 1.02
Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res (2010) 0.98
Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother (2014) 0.98
Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother (2010) 0.97
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol (2010) 0.97
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol (2015) 0.96
Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. Antimicrob Agents Chemother (2011) 0.96
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J (2012) 0.96
Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics. AAPS J (2010) 0.95
Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol (2009) 0.94
Population pharmacokinetics of oral diclofenac for acute pain in children. Br J Clin Pharmacol (2008) 0.94
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL. CPT Pharmacometrics Syst Pharmacol (2014) 0.92
Model evaluation of continuous data pharmacometric models: Metrics and graphics. CPT Pharmacometrics Syst Pharmacol (2016) 0.89
Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol (2010) 0.89
A pharmacokinetic PET study of NK₁ receptor occupancy. Eur J Nucl Med Mol Imaging (2011) 0.87
Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol (2012) 0.85
Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol (2010) 0.85
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother (2013) 0.85
Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother (2014) 0.84
Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus. PLoS Comput Biol (2012) 0.84
Covariates of intravenous paracetamol pharmacokinetics in adults. BMC Anesthesiol (2014) 0.84
Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET. Br J Pharmacol (2014) 0.83
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs (2010) 0.83
Temporal linear mode complexity as a surrogate measure of the effect of remifentanil on the central nervous system in healthy volunteers. Br J Clin Pharmacol (2011) 0.83
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. J Clin Pharmacol (2011) 0.82
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Invest New Drugs (2008) 0.82
Developmental pharmacokinetics of propylene glycol in preterm and term neonates. Br J Clin Pharmacol (2013) 0.82
Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs. Br J Pharmacol (2009) 0.82
Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res (2014) 0.82
Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther (2015) 0.82
The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. Paediatr Anaesth (2014) 0.82
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol (2015) 0.81
Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. Acta Pharmacol Sin (2012) 0.81
PKreport: report generation for checking population pharmacokinetic model assumptions. BMC Med Inform Decis Mak (2011) 0.81
Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol (2014) 0.81
Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain. Br J Clin Pharmacol (2008) 0.81
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J (2015) 0.81
Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers. Antimicrob Agents Chemother (2015) 0.81
Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother (2009) 0.81
The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol (2014) 0.80
Standard Error of Empirical Bayes Estimate in NONMEM® VI. Korean J Physiol Pharmacol (2012) 0.79
Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model. Orphanet J Rare Dis (2014) 0.79
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol (2016) 0.79
Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. Eur J Clin Pharmacol (2013) 0.79
Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. Eur J Clin Pharmacol (2013) 0.78
Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers. CPT Pharmacometrics Syst Pharmacol (2015) 0.78
IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach. Am J Physiol Endocrinol Metab (2010) 0.78
Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol (2012) 0.78
Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. Eur J Clin Pharmacol (2014) 0.78
Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered. Antimicrob Agents Chemother (2012) 0.78
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure. J Pharm Sci (2010) 0.78
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine. AAPS J (2010) 0.78
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. AAPS J (2010) 0.78
Modeling Testosterone Circadian Rhythm in Hypogonadal Males: Effect of Age and Circannual Variations. AAPS J (2015) 0.78
Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol (2016) 0.78
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits. Eur J Drug Metab Pharmacokinet (2017) 0.77
Evaluation of an extended grid method for estimation using nonparametric distributions. AAPS J (2009) 0.77
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. Br J Clin Pharmacol (2016) 0.77
Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. PLoS One (2016) 0.77
Romiplostim dose-response in patients with myelodysplastic syndromes. Br J Clin Pharmacol (2013) 0.77
Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol (2014) 0.77
Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model. Acta Anaesthesiol Scand (2014) 0.77
Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol (2014) 0.76
Use of a linearization approximation facilitating stochastic model building. J Pharmacokinet Pharmacodyn (2014) 0.76
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol (2014) 0.76
An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol (2013) 0.76
Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. Eur J Clin Pharmacol (2016) 0.76
Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. AAPS J (2011) 0.76
Investigating Clinically Adequate Concentrations of Oseltamivir Carboxylate in End-Stage Renal Disease Patients Undergoing Hemodialysis Using a Population Pharmacokinetic Approach. Antimicrob Agents Chemother (2015) 0.76
Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol (2016) 0.76
Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. Eur J Clin Pharmacol (2016) 0.75
Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. Clin Pharmacol Ther (2012) 0.75
Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol (2016) 0.75
Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass. Anesthesiology (2015) 0.75
Development of a population pharmacokinetic model of prucalopride in children with functional constipation. Pharmacol Res Perspect (2016) 0.75
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies. PLoS One (2015) 0.75
Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System. J Pharmacol Exp Ther (2016) 0.75
Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. AAPS J (2015) 0.75
Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. Br J Clin Pharmacol (2015) 0.75
Exploring population pharmacokinetic modeling with resampling visualization. Biomed Res Int (2014) 0.75
A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults. Antimicrob Agents Chemother (2014) 0.75
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. Br J Clin Pharmacol (2014) 0.75
Population pharmacokinetics and analgesic potency of oxycodone. Br J Clin Pharmacol (2016) 0.75
Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. Br J Clin Pharmacol (2016) 0.75
Time-course analysis of main markers of primary infection in cats with the feline immunodeficiency virus. Comput Math Methods Med (2012) 0.75